Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Management article
-
Reference no. F00305
Published by: Harvard Business Publishing
Published in: "Harvard Business Review - Forethought", 2000

Abstract

When Biogen received approval for a breakthrough drug for treating multiple sclerosis, it had to quickly get the product to market. So it circumvented the traditional supply chain and joined with partners to become a virtual manufacturer.

About

Abstract

When Biogen received approval for a breakthrough drug for treating multiple sclerosis, it had to quickly get the product to market. So it circumvented the traditional supply chain and joined with partners to become a virtual manufacturer.

Related